Definitive Healthcare (NASDAQ:DH) Given New $3.00 Price Target at Barclays

Definitive Healthcare (NASDAQ:DH) had its price target decreased by Barclays from $4.00 to $3.00 in a research note published on Monday morning,Benzinga reports. Barclays currently has an underweight rating on the stock.

Other equities analysts also recently issued reports about the company. Needham & Company LLC restated a “hold” rating on shares of Definitive Healthcare in a report on Thursday, January 16th. Stephens assumed coverage on Definitive Healthcare in a research note on Friday, December 20th. They set an “equal weight” rating and a $5.00 target price on the stock. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $5.61.

Definitive Healthcare Price Performance

Shares of NASDAQ:DH opened at $2.83 on Monday. The stock has a market cap of $326.93 million, a PE ratio of -0.91, a price-to-earnings-growth ratio of 4.06 and a beta of 1.45. Definitive Healthcare has a 1-year low of $2.58 and a 1-year high of $9.11. The company has a current ratio of 2.49, a quick ratio of 2.49 and a debt-to-equity ratio of 0.33. The stock’s fifty day simple moving average is $4.63 and its two-hundred day simple moving average is $4.48.

Definitive Healthcare (NASDAQ:DH) last posted its earnings results on Thursday, February 27th. The company reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.04). The company had revenue of $62.29 million for the quarter, compared to analysts’ expectations of $60.60 million. Definitive Healthcare had a negative net margin of 142.38% and a positive return on equity of 1.76%. As a group, analysts forecast that Definitive Healthcare will post 0.16 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Victory Capital Management Inc. lifted its position in Definitive Healthcare by 6.5% in the 3rd quarter. Victory Capital Management Inc. now owns 542,170 shares of the company’s stock valued at $2,424,000 after acquiring an additional 33,161 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new position in Definitive Healthcare in the 3rd quarter valued at approximately $512,000. Intech Investment Management LLC acquired a new stake in shares of Definitive Healthcare during the third quarter worth $55,000. Massachusetts Financial Services Co. MA boosted its stake in Definitive Healthcare by 36.8% during the third quarter. Massachusetts Financial Services Co. MA now owns 6,053,233 shares of the company’s stock worth $27,058,000 after acquiring an additional 1,626,813 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Definitive Healthcare by 5.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 436,132 shares of the company’s stock valued at $1,950,000 after buying an additional 23,706 shares in the last quarter. Institutional investors and hedge funds own 98.67% of the company’s stock.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.